Cantargia: New Biomarker Results in Pancreatic Cancer - Redeye
Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.
ANNONS
Redeye believes the new biomarker results with nadunolimab to be presented at the AACR Annual Meeting 2023 validate the scientific understanding of nadunolimab.